| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.05. | Sona Nanotech Announces Clinical Strategy With Two THT Combination Therapy Studies In Melanoma | 4 | CNW | ||
| SONA NANOTECH Aktie jetzt für 0€ handeln | |||||
| 27.04. | Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences | 1 | CNW | ||
| 16.04. | Sona Nanotech Inc: Sona Nanotech appoints Smylie, Trites to advisory board | 1 | Stockwatch | ||
| 16.04. | Sona Nanotech Announces Appointment of Two Leading Oncologists To Its Scientific Advisory Board | 1 | CNW | ||
| 13.04. | Sona Nanotech Inc: Sona Nanotech upbeat about THT's effect on tumours | 2 | Stockwatch | ||
| 13.04. | Sona Nanotech Clinical Cancer Study Tissue Analysis Confirms Tumor Priming And Suggests Potential Immunotherapy Synergies | 2 | CNW | ||
| 08.04. | Sona Nanotech Inc: Sona says THT shows strong combo cancer efficacy | 3 | Stockwatch | ||
| 07.04. | Sona Nanotech's THT Cancer Therapy Demonstrates Strong Efficacy And Durability In Combination with Immunotherapy In Peer-reviewed Preclinical Study | 1 | CNW | ||
| 17.03. | Sona Nanotech Inc: Sona Nanotech to hold investor webinar March 18 | 3 | Stockwatch | ||
| 16.03. | Sona Nanotech To Hold Investor Webinar To Discuss Follow-up Data From First-in-human Cancer Therapy Study | 1 | CNW | ||
| 20.10.25 | Sona Nanotech Inc.: Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study | 678 | Newsfile | Halifax, Nova Scotia--(Newsfile Corp. - October 20, 2025) - Sona Nanotech Inc., (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), is pleased to announce the completion of its first-in-human clinical... ► Artikel lesen | |
| 17.10.25 | Sona Nanotech Inc.: Sona Nanotech To Host Investor Webinar To Discuss Clinical Study | 1.168 | Newsfile | Halifax, Nova Scotia--(Newsfile Corp. - October 17, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that it will host a webinar on Monday, October 20th at noon... ► Artikel lesen | |
| 25.08.25 | Sona Nanotech Inc.: Sona Provides Update on First-In-Human Clinical Trial | 958 | Newsfile | Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies... ► Artikel lesen | |
| 23.07.25 | Sona Nanotech Inc.: Sona Announces Canadian Melanoma Clinical 'Pilot' Study Ethics Approval | 861 | Newsfile | Halifax, Nova Scotia--(Newsfile Corp. - July 23, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies... ► Artikel lesen | |
| 07.07.25 | Sona Nanotech Inc.: First Patient Dosed in Early Feasibility Study Trial of its Cancer Therapy | 1.016 | Newsfile | Halifax, Nova Scotia--(Newsfile Corp. - July 7, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") an oncology-focused life sciences company developing innovative therapies... ► Artikel lesen | |
| 27.06.25 | Sona Nanotech Inc.: Sona Announces Ethics Committee Approval For Melanoma Clinical Trial | 781 | Newsfile | Halifax, Nova Scotia--(Newsfile Corp. - June 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies... ► Artikel lesen | |
| 16.06.25 | Sona Nanotech Inc.: Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy | 711 | Newsfile | First Patients Expected to be Enrolled This MonthHalifax, Nova Scotia--(Newsfile Corp. - June 16, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") an oncology-focused life... ► Artikel lesen | |
| 27.05.25 | Sona Nanotech Inc.: Sona Successfully Completes FDA-Required Toxicity Study | 1.013 | Newsfile | Halifax, Nova Scotia--(Newsfile Corp. - May 27, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce positive results from a required preclinical safety... ► Artikel lesen | |
| 15.05.25 | Sona Nanotech Inc.: Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial | 1.312 | Newsfile | Halifax, Nova Scotia--(Newsfile Corp. - May 15, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the successful completion of bacterial endotoxin... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 19,160 | +4,70 % | EILMELDUNG bei Formycon: Könnte die Aktie jetzt komplett einbrechen? - Was Sie jetzt noch wissen müssen | ||
| OBDUCAT | 0,045 | +4,65 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen | |
| SOLESENCE | 1,310 | +5,65 % | SOLESENCE, INC. - 10-Q, Quarterly Report | ||
| ONTO INNOVATION | 236,00 | -0,38 % | Why Onto Innovation (ONTO) Might be Well Poised for a Surge | ||
| RIBER | 12,720 | +4,61 % | Riber: Margen steigen, KI-Boom treibt - Hidden Champion vor nächsten Kursschub? | Hightech "Made in France" mit Rückenwind durch KI und Photoniks: Riber verbessert trotz leicht rückläufigem Umsatz deutlich seine Profitabilität und könnte vor einem neuen Wachstumszyklus stehen. Riber... ► Artikel lesen | |
| KOPIN | 4,340 | -4,51 % | Fabric.AI (Nasdaq: FABC) and Kopin Corporation (Nasdaq: KOPN) Appoint Bill Maffucci to Lead Development of Neural I/o MicroLED Optical Interconnect Chip Program | NEW YORK, NY, May 06, 2026 (GLOBE NEWSWIRE) -- Fabric.AI (Nasdaq: FABC) ("Fabric.AI" or "the Company"), an AI infrastructure company developing a suite of fabless semiconductor technologies for next-generation... ► Artikel lesen | |
| SMOLTEK NANOTECH | 0,210 | -7,49 % | Communiqué from the 2026 Annual General Meeting of Smoltek Nanotech Holding AB (publ) | ||
| GOMSPACE | 1,629 | -2,34 % | GomSpace A/S: GomSpace reports a solid Q1 with 43% revenue growth and positive EBITDA | GomSpace continues to demonstrate strong revenue growth, delivers positive EBITDA, and takes first step toward delivering sovereign satellite communication solutions in Ukraine.STOCKHOLM... ► Artikel lesen | |
| VEECO INSTRUMENTS | 52,48 | +0,31 % | CEO At Veeco Instruments Sells $5.96M Of Stock | ||
| GAUZY | 0,830 | 0,00 % | GAUZY LTD: Gauzy Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency | TEL AVIV, Israel, March 20, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced that on March 17... ► Artikel lesen | |
| ACACIA RESEARCH | 3,980 | +1,53 % | Acacia Research Q1 2026 slides show mixed results, strong liquidity | ||
| FENDX TECHNOLOGIES | 0,149 | -1,97 % | FendX Technologies Inc.: FendX Engages Innovotech for Regulatory Pathway Assessment of Its Coated Foley Catheter Program | Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), a technology company developing surface-protection... ► Artikel lesen | |
| DOTZ NANO | 0,023 | +3,18 % | XFRA 57N: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ZENTEK | 0,900 | +21,62 % | Zentek Ltd.: Zentek's ZenGUARD Enhanced Air Filters Now Available for Direct Procurement by All Federal Departments and Agencies | Guelph, Ontario--(Newsfile Corp. - May 13, 2026) - Zentek Ltd. (TSXV: ZEN) (NASDAQ: ZTEK) ("Zentek" or the "Company") is pleased to announce that Innovative Solutions Canada ("ISC") has added ZenGUARD... ► Artikel lesen | |
| NANOVIRICIDES | 1,350 | +4,65 % | Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides | SHELTON, CT / ACCESS Newswire / May 11, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the... ► Artikel lesen |